Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 4/20 | 0.39 |
| ▸ | RBP4 | P02753 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL785726 | 0.91 | TAS1R3 (0.41) | KMT2AMEN1F10MAPT | |
| SCHEMBL785701 | 0.90 | TAS1R3 (0.41) | KMT2AMEN1ATMNPC1F10 | |
| SCHEMBL785666 | 0.87 | TRPV1 (0.44) | F10 | |
| SCHEMBL785695 | 0.87 | ALDH1A1 (0.41) | KMT2AMEN1ALDH1A1GAAF10 | |
| SCHEMBL785659 | 0.87 | ALDH1A1 (0.39) | KMT2AMEN1ALDH1A1GAAF10 | |
| SCHEMBL784882 | 0.87 | ALDH1A1 (0.41) | KMT2AMEN1ALDH1A1GAAF10 | |
| SCHEMBL785862 | 0.86 | ALDH1A1 (0.42) | KMT2AMEN1ALDH1A1GAAF10 | |
| SCHEMBL785511 | 0.86 | TAS1R3 (0.52) | KMT2AALDH1A1GAAATMMAPT | |
| SCHEMBL785926 | 0.86 | TRPV1 (0.42) | KMT2AMEN1ALDH1A1NPC1F10 | |
| SCHEMBL785738 | 0.85 | ALDH1A1 (0.45) | KMT2AMEN1ALDH1A1NPC1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | claimed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | KMT2A 2222/4885MEN1 2563/4885ALDH1A1 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.